Latest Pharma and Biotech News
Pharmaceutical
25 November 2024 In what could be construed to be India's quest for pharmaceutical supremacy, a clarion call has been made for the country to set its indigenous standards.
Today's issue
Refine Search
article
Japanese drug major Astellas Pharma has announced a strategic investment to support the advancement of Poseida Therapeutics’ commitment to redefining cancer cell therapy. The news pushed Poseida’s shares up as much as 24% to $2.69. 9 August 2023
Biotechnology
South Korean vaccine developer SK bioscience’s shares were up 4.6% at 84,500 won, after it announced its decision to make an equity investment of around $85 million in US biotech Novavax. 9 August 2023
Biotechnology
Sino-American biotech Terns Pharmaceuticals yesterday revealed positive top-line results from the Phase IIa DUET clinical trial of TERN-501, both alone and in combination with TERN-101, for the treatment of non-alcoholic steatohepatitis (NASH). 9 August 2023
Pharmaceutical
The competition to address two areas of huge unmet medical need is heating up, and Eli Lilly has a chance of being the leader in both. 8 August 2023
Pharmaceutical
Germany’s Bayer might have a new chief executive in Bill Anderson, but many of the challenges faced by his predecessor Werner Baumann remain. 8 August 2023
Biotechnology
US cancer-focused biotech Foghorn Therapeutics today announced that Dr Alfonso Quintás-Cardama will join the company as chief medical officer, on September 11, 2023. 8 August 2023
Biotechnology
Swiss ophthalmology specialist Oculis Holding today released positive top-line results from its Phase III OPTIMIZE trial with OCS-01 eye drops. 8 August 2023
Generics
The Indian pharmaceutical industry has made significant progress in reducing its dependency on China for active pharmaceutical ingredients (APIs). 8 August 2023
Pharmaceutical
US clinical-stage drug developer Vistagen saw its shares go into the stratosphere, up as much as 1,272% and closing yesterday on a 677% boost to $13,05, after it released new data on its social anxiety disorder (SAD) candidate that had disappointed in a readout a year ago. 8 August 2023
Pharmaceutical
Shares in Danish diabetes giant Novo Nordisk have risen sharply after positive top-line data were announced from the SELECT cardiovascular outcomes trial. 8 August 2023
Biosimilars
German companies Fresenius Kabi and Formycon have reached a settlement with US healthcare giant Johnson & Johnson for the USA, concerning FYB202, a proposed biosimilar to Stelara (ustekinumab). 8 August 2023
Biotechnology
Shares of Ginkgo Bioworks were down more than 9% at $1.96 in pre-market activity this morning, despite the company announcing a potentially lucrative collaboration. 8 August 2023
Pharmaceutical
UK-based Astex Pharmaceuticals, a pharma company focused on the discovery and development of small molecules for oncology and central nervous system disorders, has expanded its deal with Merck & Co. 8 August 2023
Biotechnology
The dyslipidemia market will be driven by the launch of therapies with promising efficacies and new mechanism of actions, as well as the growth of the dyslipidemia population. 8 August 2023
Biotechnology
Nektar Therapeutics’ shares closed up a massive 82.6% at $0.98 yesterday, after it revealed announced that efficacy data previously generated by former partner Eli Lilly for Rezpeg (rezpegaldesleukin) that were presented at the September 2022 EADV Congress were incorrectly calculated by Lilly. 8 August 2023
Biotechnology
The recent Life Sciences Competitiveness Indicators published by the UK government suggests that international investors are abandoning the country’s life sciences sector as excessive revenue clawback rates start to bite. 7 August 2023
Biotechnology
San Diego, USA-based cancer focussed biotech Viracta Therapeutics today announced the appointment of Dr Darrel Cohen, as chief medical officer (CMO), with immediate effect. 7 August 2023
Biotechnology
US cancer drug developer Ikena Oncology today announced the closing of its acquisition of privately-held clinical-stage biotech Pionyr Immunotherapeutics in an all-stock transaction. 7 August 2023
Biotechnology
Increased activity and investment in the development of antibody-drug conjugates (ADCs) has been evident in the oncology market in the past two to three years. 7 August 2023
Biotechnology
The US Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has voted unanimously by 10 to 0 to recommend routine use of Beyfortus (nirsevimab-alip). 7 August 2023
All news
Biotechnology
Clinical-stage US CAR-T therapies developer Poseida Therapeutics saw its shares skyrocket 227% to $9.36 pre-market today, on the news of a proposed takeover by Swiss pharma giant Roche. 26 November 2024
Pharmaceutical
Shares in US biotech major Amgen were 11% lower early on Tuesday. 26 November 2024
Biotechnology
Replimune, a clinical-stage biotech focused on oncolytic immunotherapies, has announced plans to raise $125 million through a public offering. 26 November 2024
Biotechnology
Chinese gene therapy firm Kanglin Biotechnology has completed a $20 million series A financing round, with the money earmarked for KL003, an innovative treatment for blood disorders. 26 November 2024
Biotechnology
BRL Medicine, a Shanghai-based biotechnology company specializing in cell and gene therapies, has raised nearly 200 million yuan ($27 million) in a series B+ round led by CSPC Fund. 26 November 2024
Biotechnology
Italian oncology focused biotech Nerviano Medical Sciences yesterday announced that it has successfully negotiated with Germany’s Merck KGaA to buy back the full world-wide rights of NMS 293 (also known as NMS-03305293). 26 November 2024
Biotechnology
South African-Australian private equity firm LeapFrog Investments has announced the close of its fourth fund (Fund IV), with commitments and designated co-investments totalling $1.02 billion. 26 November 2024
Biotechnology
Pyxis Oncology has announced encouraging preliminary data from a Phase I trial of PYX-201, its lead antibody-drug conjugate (ADC), in solid tumors. 26 November 2024
Biotechnology
The Phase III SKYSCRAPER-01 trial has missed its primary endpoint, Swiss cancer giant Roche has reported. 26 November 2024
Pharmaceutical
Spanish HIV focused immunotherapies company AELIX Therapeutics, a spin-off of IrisCaixa, has announced the acquisition of its investigational assets related to the HTI therapeutic HIV vaccine by US antiviral specialist Gilead Sciences. 26 November 2024
Biotechnology
US biopharma Biohaven has provided an update regarding the taldefgrobep alfa development programs in spinal muscular atrophy (SMA) and obesity. 25 November 2024
Biotechnology
Cassava Sciences, a US biotech developing a novel, investigational treatment for Alzheimer’s disease (AD) dementia, was trading 83% lower at midday on Thursday. 25 November 2024
Pharmaceutical
Positive top-line results from the Phase III ZENITH study evaluating Winrevair (sotatercept-csrk) in adults with pulmonary arterial hypertension (PAH, WHO Group 1) functional class (FC) III or IV at high risk of mortality, were released today by US pharma giant Merck & Co. 25 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for belantamab mafodotin in combinations with bortezomib plus dexamethasone (BorDex [BVd]) and pomalidomide plus dexamethasone (PomDex [BPd]) for multiple myeloma patients who have received at least one prior line of therapy. 25 November 2024
Pharmaceutical
The US Food and Drug Administration (FDA) has approved Imkeldi (imatinib) oral solution, the first oral liquid form of imatinib to treat certain forms of leukemia and other cancers, from privately-held US-Ireland-based pharmaceutical company Shorla Oncology. 25 November 2024
Pharmaceutical
Specialist pre-clinical contract research organization (CRO) and ion channel screening company Metrion Biosciences has announced the appointment of Lee Patterson as its new chief executive. 25 November 2024
Pharmaceutical
Levothyroxine, a widely prescribed treatment for hypothyroidism, may contribute to bone loss in older adults, according to new research presented at the Radiological Society of North America’s (RSNA) annual meeting. 25 November 2024
Biotechnology
Danish biotech Adcendo today announced the successful closing of an oversubscribed $135 million Series B financing round. 25 November 2024
Biotechnology
StemCyte, a subsidiary of StemCyte International, has secured approval from the US Food and Drug Administration for Regenecyte, a cord blood-derived stem cell therapy. 25 November 2024
Biotechnology
A patient in Neurogene’s ongoing Phase I/II trial for Rett syndrome—who was dosed on November 5 with 3E15 vg of NGN-401—has now died from a treatment-related serious adverse event (SAE). 25 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze